For patients receiving biologic infusions, a five-minute injection can mean an entire day lost. Early morning drives to the hospital, hours spent waiting alongside other patients, and exposure risks that are especially dangerous for someone whose immune system is already compromised. It’s an experience that has stayed the same for decades, even as the drugs themselves have changed dramatically.
In this Spotlight Interview, Ventura Solutions Founder and CEO Chuck Ventura sits down with Dr. Andrei Yosef, President and General Manager of LTS Device Technologies, to explore why that experience is finally starting to change, and what the shift from IV to subcutaneous, and from clinic to home, means for pharma companies, healthcare systems, and patients.
Andrei brings more than 20 years of experience building drug delivery devices to the conversation, along with a personal reason for doing this work. Watching a family member endure repeated, exhausting hospital visits for what should have been a simple injection led him to ask a question that became the foundation of his career: if the technology exists to do this better, why aren’t we using it? That question led him to found Sorrel Medical, now part of LTS, and it still drives how he thinks about device design today.
Key Topics Covered:
- [02:35] The Story Behind the Mission – Why watching a family member’s cancer treatment turn a five-milliliter injection into a half day hospital visit inspired the creation of a wearable drug delivery company
- [09:49] A Revolution, Not an Evolution – How the number of biologics in development grew from roughly 200 in 2014 to more than 2,000 in 2024, and what that growth means for the future of drug delivery
- [10:20] Why IV Comes First, and Why SubQ Is Catching Up – The clinical and practical reasons most biologics launch as IV therapies, and the safety, comfort, and pharmacokinetic advantages pushing more of them toward subcutaneous
- [12:17] Biosimilars Change the Rules of Differentiation – With more than 30 biosimilars approved in the past year and a half, up from one or two per year historically, and each biologic expected to face eight to twelve biosimilar competitors, the device is often the only place left to differentiate a product that must otherwise match its reference drug exactly
- [14:15] Building the First Wearable Biosimilar On-Body Injector – The inside story of bringing a biosimilar on-body injector to market for the first time, including the regulatory conversations required to improve on the reference device without triggering new scrutiny, and how it went on to capture share from a market a single wearable had protected for years
- [31:15] Designing for a Patient Who Will Never Become an Expert – Why a device used once every few weeks demands a completely different design philosophy than one used daily, and how LTS approached this by aiming to make a biologic injection as simple as applying a band aid
- [22:08] Solving for Volume and Viscosity – How LTS’s on-body platforms range from under 1 mL to 50 mL, with a sweet spot between roughly 4.5 mL and 20 mL, a gap not well addressed by autoinjectors or traditional syringes
- [32:35] What Happens When Drug Delivery Gets Connected – Andrei’s take on why medical devices still lag behind the rest of consumer technology, and how data capture, adherence tracking, and direct to home delivery could combine to make hospital visits unnecessary for far more patients
The conversation points to a future that already feels close: a patient at home, receiving a package, applying a wearable injector on their own, with every detail of that dose already logged and visible to their care team. Getting there requires pharma companies to think beyond the drug itself, toward device technology, human factors, regulatory strategy, and the complete patient experience
For organizations developing biologics, biosimilars, or next generation combination products, understanding these shifts now can shape device selection, development strategy, and commercialization decisions before competitors get there first
Explore Our Combination Product Solutions
Ventura Solutions provides end to end support for combination product and medical device development, helping organizations integrate drug and device development while navigating design controls, risk management, human factors, regulatory requirements, and commercialization.
Whether you need combination product consulting, engineering support, staffing, or training, our team works alongside pharmaceutical and medical device organizations to help develop and sustain safe, effective, patient centered products.
👉Click here to learn more about our integrated combination product services.
For patients receiving biologic infusions, a five-minute injection can mean an entire day lost. Early morning drives to the hospital, hours spent waiting alongside other patients, and exposure risks that are especially dangerous for someone whose immune system is already compromised. It's an experience that has stayed the same for decades, even as the drugs themselves have changed dramatically. In this Spotlight Interview, Ventura Solutions Founder and CEO Chuck Ventura sits down with Dr. Andrei Yosef, President and General Manager of LTS Device Technologies, to explore why that experience is finally starting to change, and what the shift from IV to subcutaneous, and from clinic to home, means for pharma companies, healthcare systems, and patients. Andrei brings more than 20 years of experience building drug delivery devices to the conversation, along with a personal reason for doing this work. Watching a family member endure repeated, exhausting hospital visits for what should have been a simple injection led him to ask a question that became the foundation of his career: if the technology exists
